

Embolic Protection In Carotid Stenting

Paul Hsien-Li Kao, MD

Assistant Professor, Cardiology

Director, Cardiac Catheterization Lab

National Taiwan University Hospital

Taipei, Taiwan


Carotid artery stenosis

- **Responsible for 20-30% of ischemic strokes**
- **Spontaneous distal embolism is the mechanism causing symptoms**
 - Transient ischemic attacks
 - Amaurosis fugax
 - Ischemic stroke
- **Symptomatic with DS>70%**
 - Risk of stroke 12-13% in the first year, 30-37% in 5y
 - 26% stroke rate in the first year if DS>90%
- **Treatment options**
 - Antiplatelet and risk factor modification
 - Surgical endarterectomy (CE)
 - Endovascular stenting (CS)



Carotid endarterectomy (CE)

- **Proven by NASCET, ACAS, and ECST**
 - 30d peri-procedural stroke/death rate 5-8%
 - Stroke risk reduction 60-70% in 3-5y
- **30d peri-operative morbidity is high**
 - Cranial nerve palsy 6-8%
 - Hematoma/infection 3-8%
 - CV problems 1-4%
 - Total medical complication 10-20%
- **Trial results do not apply to the real world**
 - Operator experience
 - Surgical risk profile of patient



Carotid stenting (CS)

- **First described in 1987, with rationales of**
 - **Metallic buttressing maintains vessel patency**
 - **Meshwork scaffolding the plaque**
 - **Neointimal formation generates a non-thrombotic surface**
 - **Although the plaque is not removed from the vessel wall, it is “excluded”**
- **Despite skeptics from the surgical society, the procedure gained wide popularity among neurologists, interventional radiologists, and cardiologists**

Symptomatic left ICAS



73M repeated TIA, CAD, old MI


Global experience

Wholey MH, et al. CCI 2003;60:259

- **12,393 CS procedures in 11,243 patients at 53 centers worldwide since 1997**
- **Registry with “real world” demographics**
- **Technical success rate 98.9%**
- **53.2% lesions symptomatic**
- **Peri-procedural event (%)**
 - **Minor stroke** **2.14**
 - **Major stroke** **1.20**
 - **Procedure-related death** **0.64**
 - **Non-related death** **0.77**
 - **Total stroke/death** **4.75**

30d stroke and procedure-related death


Wholey MH, et al. CCI 2003;60:259



Actual stroke prevention

Wholey MH, et al. CCI 2003;60:259

■ 9,419 (85%) of the patients were followed for more than 12m




Procedural embolism

- **The most devastating complication of CS**
- **Emboic materials are released in all steps of the procedure**
- **Surgeons criticize CS for putting patients at risk for embolism, while CE protects with clamping or shunting**

Embolic prevention in CS


- **Adjuvant pharmacology**
 - Antiplatelet
 - Preprocedural anticoagulation
- **Procedural technique**
 - Delicate wiring
 - Direct stenting
- **Device design**
 - Dedicated carotid device
- **Embolic protection device (EPD)**
 - Filter
 - Distal occlusion
 - Proximal occlusion

NTUH experience of EPD



Distal occlusion

- **Balloon on wire crosses lesion**
- **Inflation before and throughout angioplasty to stop anterograde flow**
- **The wire shaft serves as angioplasty wire**
- **Debris released stayed in the stagnant column of blood**
- **Aspiration to remove debris**
- **Lesion has to be crossed first**
- **Patient tolerance**
- **Potential distal vessel trauma**





PercuSurge GuardWire Plus



- **Better crossing profile than other distal devices**
- **One size fits all (3-6 mm)**
- **Emboli particle size irrelevant**
- **Device handling and preparation is complex**



GuardWire Case




GuardWire Case




Proximal occlusion

- **Balloon-necked catheter placed proximally**
- **Anterograde flow stopped or diminished before lesion manipulation**
- **Routine angioplasty instruments through catheter lumen**
- **Debris released removed by aspiration**
- **Large groin access**
- **Patient tolerance**




Invatec MoMA device


- **10Fr balloon-necked catheter for CCA occlusion**
- **Extension balloon for ECA occlusion**
- **Catheter lumen serves as working channel**
- **Protection before lesion is touched**
- **Virtually no size limit on the target vessel**
- **Choice of any wire, balloon, and stent**
- **Device handling and preparation is complex**



MoMA case




MoMA case



Filter

- **Filter crosses the lesion in a constrained fashion**
- **Deployment before angioplasty**
- **Wire shaft serves as angioplasty wire**
- **Anterograde flow maintained while debris captured**
- **Final filter retrieval**
- **Lesion has to be crossed first**
- **Potential distal ICA trauma**
- **Emboli smaller than pore size escape filtration**





BSc EPI FilterWire



- **Fishnet silicon filter membrane with pore size 80 (EX) and 110 micron (EZ) with Nitinol mouth loop**
- **Same monorail sheath for delivery and capture**
- **Easy device preparation and handling**
- **One size fits all (3-5.5mm)**
- **Coaxiality and pocket capacity**



FilterWire case



FilterWire case





Cordis AngioGuard XP

- **Nitinol filter basket with silicon membrane and pore size 100 micron**
- **Good coaxiality and self-centering ability**
- **Pocket capacity**
- **Vessel spasm**



AngioGuard case



Abott MedNova EmboShield

- **Independent stepped guide wire and detached filter**
- **Polyurethane filter membrane (pore size 150 micron) and nitinol basket framework**
- **Better wire maneuverability**
- **Large pocket capacity**
- **Rigid filter**
- **Complex device preparation**



NTUH protected CS experience


	Non-protected (n=174)	Protected (n=143)
Sex, M/F	123/51	111/32
Age, y	72 ± 8	74 ± 8
HTN, %	71	78
DM, %	28	31
HLP, %	44	48
Smoking, %	46	55
Symptomatic, %	65	66
NASCET exclusion, %	70	67
CCA diameter, mm	7.5 ± 1.2	7.3 ± 1.0
ICA diameter, mm	5.4 ± 0.8	5.4 ± 0.8
Lesion length, mm	21 ± 9	20 ± 7
DS, %	86 ± 10	90 ± 7
Final RS, %	13 ± 8	12 ± 7

NTUH protected CS experience

	Non-protected (n=175)	Protected (n=143)
Tech. success, %	99.4	99.3
Procedural stroke/death, %	4.6	2.1
Ipsi. stroke, %	3.4	0.7
Total stroke, %	4.0	1.4
Death, %	0.6	0
Follow-up, m	42 ± 11	16 ± 12
F/u rate, %	98	99
New stroke/death, %	6.9	2.8
Ipsi. Stroke, %	2.9	0.7
Total stroke, %	4.0	0.7
Death, %	3.4	1.4
Angio. restenosis, %	2.9	1.4

30d stroke and procedure-related death

Wholey MH, et al. CCI 2003;60:259



NTUH EPD selection

	Distal balloon	Proximal balloon	Filter
Isolated ICA	+	+	+
Contr. occlusion	-/+	-/+	+
Diseased CCA	+	-/+	+
Large ICA >6-8 mm	-/+	+	-
String sign	-/+	+	-
Insufficient Willis	-/+	-/+	+
Long tortuous lesion	-/+	+	-
Brachial approach	+	-	+

Does EPD really work?

■ PercuSurge: Henry M et al CCI 2004;61:293

- 268 lesions in 242 patients
- Debris aspirated in all, with mean particle size 250 μm (56-2652 μm) and number 74 (7-145)
- 30d death/stroke rate 2.3%

■ EmboShield: SECuRITY registry TCT 2003

- 305 high-risk patients with Xact + EmboShield
- 30d stroke/death/MI 7.2%


■ Accunet: ARCHeR 2 registry TCT 2003

- 278 high-risk patients with OTW Acculink + Accunet
- 30d major stroke/death rate 2.5%
- New ipsi. stroke upto 12-month 0.4%

SAPPHIRE trial

Yadav JS. ACC 2003

- **Parallel randomized comparison and registries of CS under EPD vs. CE in 29 US sites**
- **Designed to look at both real-world as well as randomization-eligible patients**



SAPPHIRE randomization 30d

Yadav JS. ACC 2003

	CS	CE	P
Death	0.6%	2.0%	0.36
Stroke	3.8%	5.3%	0.59
MI (Q/non-Q)	2.6%	7.3%	0.07
Death/stroke/MI	5.8%	12.6%	<0.05
TIA	3.8%	2.0%	0.5
Major bleeding	8.3%	10.6%	0.56
Cranial nerve injury	0.0%	5.3%	<0.01

SAPPHIRE randomization 1y

Yadav JS. ACC 2003

	CS (N=159)	CE (N=151)	P
Death (%)	11 (6.9)	19 (12.6)	0.12
Stroke	9 (5.7)	11 (7.3)	0.65
Major ipsi.	0	5 (3.3)	0.03
Major non-ipsi.	1 (0.6)	1 (0.7)	1
Minor ipsi.	6 (3.8)	3 (2.0)	0.5
Minor non-ipsi.	3 (1.9)	3 (2.0)	1
MI	4 (2.5)	12 (7.9)	0.04
QMI	0	2 (1.3)	0.24
Non-QMI	4 (2.5)	10 (6.6)	0.1
MAE w/o non-neuro death >30D	9 (5.7)	19 (12.6)	<0.05
MAE w/o non-neuro death or MI >30D	8 (5.0)	11 (7.3)	0.48
Cranial n. palsy	0	7 (4.6)	<0.01
Clinically driven TLR	1 (0.6)	6 (4.0)	0.06

Conclusion

- **Procedural embolism of CS can be effectively prevented by various EPD, along with refined equipments and techniques**
- **EPD is mandatory and essential in the current standard practice**
- **Vast body of experience demonstrates CS with EPD is safe, effective, and durable in stroke prevention**
- **SAPPHIRE trial showed CS with EPD is better than CE, with more RCT's coming**